Bhatty M, et al. - Researchers sought to validate preclinical data suggesting that BRAF inhibition in conjunction with chemotherapy increases therapeutic activity. Study participants included 19 patients with advanced cancers and BRAF mutations who were enrolled into a dose-escalation study (3+3 design) administering vemurafenib (480-720 mg orally twice daily), carboplatin (area under the curve [AUC] 5-6 intravenously every 3 weeks), and paclitaxel (100-135 mg/m² intravenously every 3 weeks). Regardless of prior treatment with BRAF and/or mitogen-activated protein kinase inhibitors, the combination of vemurafenib, carboplatin, and paclitaxel demonstrated encouraging activity, predominantly in patients with advanced melanoma and BRAF^V600 mutations. In addition, the therapy was well tolerated in this study population.